Professor Milton Hearn has been awarded the prestigious 2012 Leighton Memorial Medal of the Royal Australian Chemical Institute (RACI). Hearn is the director of the Australian research council special research centre for green chemistry at Monash University, Clayton, Australia.
Professor Milton Hearn has been awarded the prestigious 2012 Leighton Memorial Medal of the Royal Australian Chemical Institute (RACI). Hearn is the director of the Australian research council special research centre for green chemistry at Monash University, Clayton, Australia.
Anne Leighton established the Leighton memorial medal award in 1965 to commemorate the lifetime achievements of her father, the chemist A. E Leighton. The silver medal, designed by the renowned medallionist Andor Meszaros, bears the profile of A. E. Leighton on one side and a design representing the chemical industry on the reverse. A. E Leighton was an ardent supporter of the RACI, playing a key role in the procurement of the RACI’s Royal Charter from England, and was the elected RACI president from 1952–1953.
Hearn has led a distinguished career, building a reputation for pioneering separation, purification and characterization of chemical and biochemical molecules. His research focuses on the elucidation of polypeptide and protein hormone structure and function and how they vary between normal and diseased states; the use of biocatalysis in directed synthesis; molecular imprinting; surface and combinatorial chemistry; and aspects of nano-biotechnology. Thanks to the work of Hearn and his colleagues, through the application of green chemistry concepts, great advances have been made in these research areas.
Hearn has authored over 450 scientific publications and a number of books. He is also the inventor or co-inventor of 20 issued patents relating to the development of analytical methods in a range of research areas in the life sciences. In addition he is an active presence in scientific publishing as a member of LCGC North America’s editorial advisory board and as associate editor or member of eight other scientific publications.
When asked to comment about the prestigious award, Hearn said, "I am honoured and delighted to receive this prestigious award. I would like to pay tribute to my highly talented colleagues who are a pleasure to work with."
The award will be officially presented to Prof Hearn at a gala awards dinner on the 23rd of November 2012.
For more information please visit:
ref=http://www.raci.org.au>www.raci.org
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.